Keloid Treatment: Comparative Effectiveness of Cryotherapy, Triamcinolone, 5-Fluorouracil, and Hyaluronidase
For keloid treatment, use intralesional triple combination therapy (triamcinolone acetonide + 5-fluorouracil + hyaluronidase) as first-line treatment, which demonstrates superior efficacy and safety compared to triamcinolone monotherapy or dual combinations.
Primary Recommendation: Triple Combination Therapy
The most recent high-quality evidence strongly supports triple therapy over monotherapy. Two 2025 randomized controlled trials demonstrate that combining triamcinolone acetonide, 5-fluorouracil, and hyaluronidase produces significantly better outcomes than triamcinolone alone 1, 2.
Specific Treatment Protocol
Intralesional injection composition:
- Triamcinolone acetonide: 0.2 cc of 40 mg/cc solution
- 5-Fluorouracil: 0.4 cc of 250 mg/5cc vial
- Hyaluronidase: 0.2 cc equivalent to 300 IU
Administration schedule:
- Inject every 3-4 weeks
- Continue for 4 sessions or until complete flattening (whichever comes first)
- Follow monthly for 3 months post-treatment
Evidence Supporting Triple Therapy
The 2025 trial by 2 showed triple combination achieved 54.55% improvement in Vancouver Scar Scale scores versus only 36.65% with triamcinolone monotherapy at final follow-up (p < 0.05). Critically, the triple therapy group experienced no telangiectasia or skin atrophy, while these complications occurred with steroid monotherapy 1.
Alternative Approaches Based on Clinical Context
For Thin, Early Keloids: Cryotherapy + Triamcinolone
When keloids are relatively thin and recent-onset, combine superficial cryotherapy with intralesional triamcinolone 3, 4. This dual approach achieved 34.3% volume reduction and 41.3% height reduction in objective measurements 4.
Cryotherapy technique:
- Apply liquid nitrogen for 15-20 seconds until 1-2 mm of circumferential skin appears frozen
- Thaw for 20-60 seconds
- Repeat freeze step once
- Immediately follow with triamcinolone injection after skin color normalizes
- Repeat every 3-4 weeks
Critical caveat: Avoid cryotherapy on eyelids, lips, nose, ears, and cartilaginous structures. Keloid formation is paradoxically listed as a potential complication of cryotherapy in other contexts 5, though when properly combined with corticosteroids for existing keloids, this risk appears mitigated.
Dual Therapy: Triamcinolone + 5-Fluorouracil (Without Hyaluronidase)
If hyaluronidase is unavailable, triamcinolone combined with 5-fluorouracil alone remains superior to triamcinolone monotherapy 6. Meta-analysis demonstrates lower scar height, reduced erythema, and fewer overall complications compared to steroid alone (p < 0.05) 6.
However, the 2025 evidence clearly shows adding hyaluronidase to this dual combination produces even better results without additional adverse effects 1, 2.
Monotherapy Considerations
5-Fluorouracil monotherapy may be preferred over triamcinolone monotherapy in cosmetically sensitive areas due to lower rates of skin atrophy and telangiectasia 7. A 2026 randomized trial showed both achieved significant scar flattening, but 5-FU demonstrated substantially better safety profile 7.
Triamcinolone monotherapy shows marginally greater mean height reduction but carries higher complication rates 7, 8. Reserve this for patients who cannot tolerate combination therapy.
Hyaluronidase Mechanism and Rationale
Hyaluronidase hydrolyzes hyaluronic acid in the intercellular ground substance, temporarily decreasing viscosity of cellular cement and promoting dispersion of injected fluids 9. This mechanism facilitates better tissue penetration and distribution of triamcinolone and 5-fluorouracil throughout the keloid, explaining the superior outcomes observed with triple therapy.
The enzyme's effect is proportionate to dosage and volume used, with dermal barrier restoration occurring within 48 hours 9. This temporary permeability enhancement allows therapeutic agents to reach deeper keloid tissue more effectively.
Treatment Algorithm
Step 1: Start with triple combination therapy (triamcinolone + 5-FU + hyaluronidase) for all keloids
- Administer every 3-4 weeks for up to 4 sessions
- Assess response at each visit using Vancouver Scar Scale
Step 2: For thin, early keloids or if triple therapy unavailable:
- Use cryotherapy (15-20 second freeze-thaw-freeze cycle) immediately followed by intralesional triamcinolone
- Avoid anatomically sensitive areas (eyelids, lips, nose, ears)
Step 3: If hyaluronidase unavailable:
- Use dual therapy with triamcinolone + 5-FU
- Expect good results but slightly inferior to triple therapy
Step 4: For cosmetically sensitive areas or patients at high risk for steroid complications:
- Consider 5-FU monotherapy over triamcinolone monotherapy
- Accept marginally lower efficacy for superior safety profile
Step 5: Monitor for recurrence:
- Follow monthly for 3 months after treatment completion
- Recurrence rates are low with combination approaches (only 1/20 patients in one series) 3
Common Pitfalls to Avoid
Do not use triamcinolone monotherapy as first-line treatment when combination therapy is available—the evidence clearly demonstrates inferior outcomes and higher complication rates 1, 2, 6.
Do not apply cryotherapy to eyelids, lips, nose, ears, or over cartilaginous structures—vascular compromise and structural damage can occur 5.
Do not expect immediate results—keloid treatment requires multiple sessions over 12-16 weeks, and patient counseling about this timeline is essential to maintain compliance.
Do not omit hyaluronidase from the triple combination if available—the 2025 evidence demonstrates this component significantly enhances outcomes without adding adverse effects 1, 2.
Adjunctive Considerations
For refractory cases after combination therapy, consider adding fractional CO2 laser or radiation therapy as consolidation 10, 8. However, start with triple combination intralesional therapy as the foundation, as this provides the most consistent evidence-based outcomes with acceptable safety profiles.
The 5-FU component is FDA-approved for topical treatment of actinic keratoses and superficial basal cell carcinomas 11, though intralesional use for keloids represents off-label application supported by substantial clinical evidence.